Double-digit growth masks margin compression; structural tailwinds ahead
The verdict, the claims that held up, the sharpest analyst exchanges, and the risks — the earnings call, decoded from the transcript.
Hold
confidence 6/10
Grade B
Double-digit revenue growth on track (H1 +13%, Q2 +16.7%); PAT growth supported (+21.8% YoY); Oil Palm FFB early double-digit met; Crop Care recovery deferred—mixed track.
Optimistic
next 1–2 quarters
Optimistic
multi-year
Q2 delivered 16.7% revenue growth and 21.8% PAT growth, meeting double-digit targets, but QoQ PAT declined 19.9% and OPM compressed to 6.7% due to cost inflation and weather headwinds. Oil Palm capex coming online Q4 FY27 and Foods B2C momentum are structural positives, but near-term margin recovery uncertain; Astec and Crop Care remain under pressure.
₹2995 Cr
Revenue · +16.7% YoY₹102.8 Cr
Reported PAT · +21.8% YoYCompressing
Margins · vs guidance: MixedDid the claims hold up?
Revenue grew 17% YoY to INR2,995 Cr
METActual YoY growth 16.7% to INR2,995 Cr
PAT up 22% to INR103 Cr
METPAT up 21.8% to INR102.8 Cr
H1 consolidated revenue grew 13% to INR5,847 Cr
METDouble-digit growth maintained; on track for FY27 double-digit guidance
Oil Palm FFB volume grew 14%
METDelivery confirms early double-digit range; on track for annual double-digit target
Double-digit FFB growth guidance holds despite El Niño
METOER recovery in Oct post-cyclone rains; H1 OER lag from June-Aug heat; trajectory recovery supports annual guidance
EBITDA margin 7.4% stable despite cost inflation
METEBITDA ₹222 Cr / Revenue ₹2,995 Cr = 7.4% (verified); OPM 6.7% reflects input cost and dairy/crop care weakness
Crop Care recovery decision by Q2-end
OVERSTATEDNo explicit recovery decision mentioned; acknowledged as tough; new product pipeline rolling out (Ashitaka, Takaib, Ghassanash). Deferred.
Earnings quality
What changed since the last call
Oil Palm capex commissioning
NewIntegrated complex with CPKO refinery opened Sept 1 Q2 (first phase). Hydrogenation/fractionation Dec. Full impact Q4 FY27 onwards, adding 2% EBITDA margin midterm.
Foods B2C acceleration
UpgradeB2C growth 50%, salience 38% (vs prior 25% → 35% trajectory stated last call). Becoming material driver; revenue momentum ahead of plan.
Crop Care recovery deferred
DowngradePrior Q1 call: 'Crop Care recovery decision by Q2-end.' Q2 call: acknowledged extended agchem weakness, cyclone impact on cotton, new product pipeline. No explicit recovery signal; timetable pushed.
Astec headwind intensity
DowngradePrior guidance 20%+ growth not referenced. Q2 call: 'challenging environment, partly domestic.' CDMO offset but enterprise demand weak; tone more cautious.
Dairy margin outlook
Downgrade6% growth insufficient vs 8% price growth noted; input costs (milk procurement, packaging) offsetting value-added mix gains. GTM revamp planned but margin relief delayed.
The Q&A
Analysts pressed hard on oil palm OER shortfall (18.9% vs 19.8% target), dairy margin trajectory, Astec guidance, and commodity price volatility (palm, PKO). Management held up: candid on weather impact (cyclones, El Niño, June-Aug heat waves), acknowledged path recovery (OER +100 bps Oct onwards), and detailed on Crop Care/Astec repositioning. Q&A was detailed, evasive on some guidance (Astec 20% target, capex status), but fundamentally honest.
Oil Palm OER shortfall — Abhijit Akella, Kotak Securities
AnsweredOER hit by June-Aug extreme heat; cyclones in Sept-Oct brought rain relief to Andhra Pradesh/Telangana region; recovery visible Sept OER near last year, Oct ahead. Target 19.7% annual achievable. H1 FFB growth double-digit; cyclone water replenishment positive. 2% EBITDA margin expansion once complex fully scales over 4-year period.
Fruit bunch volume confidence — Abhijit Akella, Kotak Securities
AnsweredYes. H1 on double-digit growth trajectory despite three of six months being extreme weather. Focus on recovery trajectory post-cyclone and scaling OER back to 19%+ by year-end. Growth maintained on discipline.
PKO refinery impact and margin timeline — Abhijit Akella, Kotak Securities
AnsweredPlant only 30 days in Q2; ramping issues. Meaningful impact Q4 FY27, scaling FY28. No Q2 contribution. Downstream scales up fully, adding ~2% to overall oil palm EBITDA margin midterm (2-3, 4-year period).
Crop care demand recovery — Abhijit Akella, Kotak Securities
AnsweredEnvironment is tough; India will see tough Rabi season given reservoir levels. Diversification strategy: new products (Ashitaka maize herbicide, Takaib insecticide, Ghassanash soybean herbicide) rolling out. 7 crop segments by FY2030 to reduce cotton/chilli dependency. Short term pain; structural correction underway.
Animal nutrition growth sustainability — Arun Kumar, Unifi Capital
AnsweredShift toward cattle feed and layer feed (8% and 100%+ growth respectively). De-prioritizing broiler feed (85-90% integrated). Growth sustainable in core segments (dairy + cattle feed). Broiler correction strategic; premiumization focus.
Dairy pricing outlook — Probal Sen, ICICI Securities
PartialNo respite visible. Temporary impact (El Niño-led heat stress on cattle milk production). Structural part: shift to value-added products (milk to curd, paneer). Milk pricing structural reset in India post-quick commerce penetration. Wait 2 quarters; next monsoon may recover. Margin recovery structural, not near-term.
Foods expansion timeline — Probal Sen, ICICI Securities
AnsweredFrozen chicken, momos (non-veg, veg), nuggets being scaled. Category creation (frozen momos, momo brands). 25% of current Foods business from new products, expected to scale 3-4 years. New product pipeline strong. 50% growth, 38% salience (vs 25% prior trajectory). Execution ahead of plan.
Oil palm commodity price volatility — Arun Kumar, Unifi Capital
PartialPKO less volatile than CPO. Biodiesel mandate parity linkage expected; crude oil down sharply post-election. Range-bound INR4,300-4,400, maybe INR4,250-4,350 next 2 months. El Niño effects Indonesia/Malaysia next 3 months uncertain. PKO OER pretty strong; scope to improve vs CPO. Difficult to predict beyond Feb-March.
Astec CDMO funnel quality — Arun Kumar, Unifi Capital
Answered~90% of inquiries converted to R&D stage. Conversion funnel strong, quality improving. ~15 products in R&D pipeline; commercialization starting this year, 1-2 per year next 2-3 years. CDMO business 50-55% target midterm. Challenging environment (Brazil, US market pressure) but fundamentals sound.
Astec enterprise demand pressure — Arun Kumar, Unifi Capital
PartialDomestic and US market toughness visible. But R&D improvements, partnership quality gains. One tough year ahead; long-run partnerships strengthen quality. Pivoting to funnel quality over volume. Can recover over 2-3 year period.
Capex execution and FY27-FY28 spend plan — Implicit in multiple Q&A
DodgedOil Palm capex came online Sept; PKO downstream Dec phase two; other capex ongoing. Full-year ₹300-350 Cr on track. No explicit H2 breakdown provided.
FY27 PBT / PAT guidance reaffirmation — Abhijit Akella, Kotak Securities
PartialHoping El Niño will not pan out; still chasing double-digit. Environment tougher than last call; honest understatement. Three months (June-Aug) extreme weather; recovery trajectory post-Sept. Two-three quarter period ahead will clarify.
Guidance
FY27 consolidated revenue: double-digit growth
MediumH1 +13%, Q2 +16.7%; trajectory supports double-digit for FY27. Reaffirmed on call but with cautious tone on El Niño recovery timing.
OPM flat/stable at ~7% despite cost inflation
LowQ2 OPM 6.7%, below prior range; inflation headwinds (dairy, feed, packaging) and seasonal pressure visible. Recovery dependent on capex contribution (Q4+) and volume growth normalization.
Oil Palm EBITDA margin +2% post-capex full scale
MediumGuidance given for 2-4 year horizon once complex fully scaled. PKO plant Q4 impact, downstream FY28 scale. Contingent on execution and commodity normalization.
Capex ₹300-350 Cr FY27
HighOil Palm integrated complex major component (CPKO + mill + biogas); phase one Sept, phase two Dec. Other capex ongoing; full-year on track per management.
Risks the call surfaced
Agchem demand weakness
HighEl Niño-led crop stress, cyclone damage in Andhra Pradesh/Telangana, dry Rabi season expected. Crop Care revenue on lower base, profitability declined. Recovery timeline uncertain; new products late-stage.
Dairy margin pressure
HighMilk procurement, feed, packaging, and logistics costs elevated. El Niño-induced heat stress reducing cattle milk productivity. 6% revenue growth insufficient to offset input cost inflation. Margin recovery dependent on structural shift to value-added and premiumization.
Astec enterprise demand weakness
MediumAstec LifeSciences facing weak enterprise demand in Brazil and US markets. CDMO business offset but not fully compensating. R&D transformation ongoing; conversion funnel 90% at R&D stage but commercialization pace uncertain.
Oil palm commodity price volatility
MediumPalm and PKO commodity prices volatile. PKO less volatile than CPO but subject to biodiesel mandate parity and crude oil linkage. El Niño effects on Indonesia/Malaysia supply uncertain next 3 months; could spike prices or suppress.
QoQ PAT decline
MediumQ2 PAT ₹102.8 Cr down 19.9% QoQ from implied Q1 ₹128 Cr. Driven by seasonal margin pressure (dairy, agchem), El Niño impact, and cost inflation. Near-term trend risky if H2 doesn't recover.
Management
Score 7/10. Clear on strategy (diversification, premiumization, capex roadmap). Transparent on near-term headwinds (El Niño, agchem weakness, margin pressure). Evasive on some guidance details (Astec 20%+ target, capex H2 breakdown, exact recovery timelines). Candid Q&A on operational challenges. H1 FY27 +13% revenue, Q2 +16.7% YoY supports double-digit guidance. Oil Palm FFB +14% in extreme weather shows discipline. Animal Nutrition +32% profit growth validates premiumization. Crop Care recovery deferred; Astec headwind acknowledged. Track record mixed but honest.
1 · Q4 FY27
Oil Palm integrated capex full online; hydrogenation/fractionation phase two December
2 · FY28 onwards
Oil Palm EBITDA margin accretion ~2% as capex scales; Foods B2C model replication
3 · Nov 2026 onwards
Crop Care new products (Ashitaka, Takaib, Ghassanash) commercialization; FY2030 7-segment target
Oil Palm capex coming online Q4 FY27 and Foods B2C momentum are structural positives, but near-term margin recovery uncertain; Astec and Crop Care remain under pressure.
Double-digit growth masks margin squeeze; structural recovery deferred to later innings
Q2 revenue surged 16.7% YoY to ₹2,995 Cr, PAT up 21.8% to ₹102.8 Cr. But profits collapsed 19.9% quarter-on-quarter, and operating margins compressed to 6.7%. The gap between headline growth and near-term execution is now the real story.
₹2,995 Cr
+16.7% YoY (+4.9% QoQ)
₹102.8 Cr
+21.8% YoY (-19.9% QoQ)
6.7%
compressed from prior ~7.4%
7.4%
stable; ₹222 Cr absolute
On the headline, Q2 looks strong: revenue up 16.7% year-over-year, PAT up 21.8%. Dig into the sequence, though, and the real story surfaces — profits fell 19.9% quarter-on-quarter, and operating margins compressed to 6.7%, their lowest in recent quarters. This is the gap that matters. Godrej is delivering double-digit revenue growth on track for full-year guidance, but the quarter-to-quarter profit decline and margin squeeze signal that the structural tailwinds (Oil Palm capex, Foods B2C, Animal Nutrition premiumization) have not yet offset the near-term headwinds (El Niño agchem weakness, dairy input cost inflation, Astec enterprise demand softness).
The quarter in context: where profit came from
H1 FY27 consolidated revenue stands at ₹5,847 Cr (+13% YoY), tracking towards the full-year double-digit guidance. Q2 itself drove ₹2,995 Cr (+4.9% QoQ), a seasonal slowdown but sequentially offset by strong Oil Palm (+28% revenue, +14% FFB volume) and Animal Nutrition (+14% revenue, +32% profit growth). The strength came from premiumization — cattle feed and layer feed surged; broiler feed was deliberately de-prioritized for margin. Foods B2C delivered 50% growth, a structural acceleration with salience now 38% of the business (vs. 25% prior trajectory).
But the margin story inverted. Operating profit margin at 6.7% (₹202 Cr EBIT on ₹2,995 Cr revenue) fell from the prior range of ~7.4%, driven by three headwinds: elevated milk procurement and feed costs in Dairy (revenue +6%, profit down due to input inflation), El Niño-driven weakness in Crop Care (revenue on lower base, profit declined), and Astec LifeSciences enterprise demand softness (CDMO offset but not fully compensating). EBITDA held at 7.4% (₹222 Cr), but the downstream operating leverage collapsed — a sign that margin relief awaits downstream (Astec CDMO scale, Crop Care new product ramp, Oil Palm capex full commissioning).
Claims vs. what holds up
Revenue grew 16.7% YoY to ₹2,995 Cr; PAT up 21.8% to ₹103 Cr
Verified: actual revenue ₹2,995 Cr (+16.7% YoY), PAT ₹102.8 Cr (+21.8% YoY). H1 consolidated ₹5,847 Cr, +13% YoY.
Supported
Double-digit consolidated revenue growth guidance for FY27 on track
H1 +13% YoY supports full-year double-digit target. Q2 +16.7% and +4.9% QoQ suggests continued momentum, though near-term volatility evident.
Supported
Oil Palm FFB volume +14% in extreme weather; OER recovery post-cyclone
OER 18.9% Q2 vs 19.8% target (miss); recovery visible in Oct ahead of prior year. FFB +14% confirmed. Annual target 19.7% stated as achievable.
Supported
Oil Palm integrated capex fully online by Q4 FY27; 2% EBITDA margin accretion midterm
CPKO refinery + mill + biogas came online Sept 1 (first phase only, 30 days in Q2). Hydrogenation/fractionation Dec. Full impact Q4 onwards. 2% accretion guidance for 2–4 year horizon post-full scale.
On track, but phased
Foods B2C 50% growth; structural channel shift underway
Verified: B2C growth 50% YoY, salience 38% vs prior 25%. Frozen chicken, momos, nuggets scaling. 25% of Foods business from new products launched <1yr.
Supported
Animal Nutrition premiumization delivering strong profit growth
Revenue +14%, segment profit +32% YoY. Cattle feed +8%, layer feed 100%+ growth. Broiler strategically de-prioritized.
Supported
Crop Care recovery decision by Q2-end (prior Q1 call)
No explicit recovery decision mentioned. Acknowledged as 'tough' quarter; new product pipeline (Ashitaka, Takaib, Ghassanash) rolling out Q4 onwards. Recovery deferred to structural plan (7 crop segments by FY2030).
Overstated / Deferred
Astec CDMO 20%+ growth on track (prior call)
20%+ target not reaffirmed on Q2 call. Enterprise demand weak in Brazil/US; CDMO offset noted but tone cautious. 90% inquiry-to-R&D conversion; ~15 products in pipeline.
Implicitly downgraded
What changed on this call
Foods B2C acceleration: Salience jumped from prior 25% trajectory to 38%, a half-year leap. Growth 50% YoY signals this is now material, not experimental. Management flagged new categories (momos, nuggets) and quick-commerce channels. Oil Palm capex tangible: First phase (CPKO refinery + mill + biogas) went live Sept 1; second phase (hydrogenation/fractionation) commissions Dec. Financial impact Q4 FY27 onwards, scaling FY28. Crop Care recovery pushed: Q1 call promised a 'recovery decision by Q2-end.' Q2 call offered no signal, only a structural diversification plan (7 crop segments by FY2030) and new product pipeline ramping Q4. Near-term remains under pressure. Astec guidance implicit downgrade: Prior 20%+ growth absent from Q2 call. Enterprise demand in Brazil/US acknowledged as 'challenging'; management pivoted to long-run partnership quality and CDMO transformation (50–55% target midterm) rather than near-term growth. Dairy margin outlook extended: Input cost inflation (milk, feed, packaging, logistics) flagged as structural. Margin recovery via premiumization and GTM revamp, but timeline extended to 2–3 quarters post-monsoon, not near-term.
The bull-bear ledger
Double-digit revenue growth on track; H1 +13%, Q2 +16.7%
Oil Palm FFB +14% YoY in extreme weather; capex first phase live
Animal Nutrition premiumization yielding 32% profit growth; thesis working
Foods B2C acceleration (50% growth, 38% salience); new products gaining traction
Management candid on headwinds (El Niño, agchem, margin pressure)
Working capital improved to 21 days from 32 days YoY
Q2 PAT -19.9% QoQ (₹102.8 Cr vs ~₹128 Cr Q1); near-term profit trend risky
OPM 6.7% compressed from prior ~7.4%; below range despite strong YoY growth
Crop Care recovery deferred; prior 'Q2-end decision' now structural plan to FY30
Dairy margin lag persisting; 6% revenue growth vs rising input costs
Astec 20%+ guidance not reaffirmed; enterprise demand soft in Brazil, US
El Niño recovery timing uncertain; OER at 18.9% vs 19.8% target
QoQ PAT decline (-19.9%): profit volatility
HighQ2 ₹102.8 Cr vs Q1 implied ~₹128 Cr signals near-term earnings instability. If H2 doesn't recover by Q4, FY27 PAT target will miss and damage guidance credibility.
OPM compression (6.7% vs prior ~7.4%): structural margin breakdown
HighMargin decline despite strong revenue growth suggests cost inflation (dairy, feed, packaging) is structural. If Oil Palm capex and Crop Care new products don't deliver accretion in H2, margins stay depressed into FY28, capping valuation.
Crop Care recovery deferred: guidance credibility
MediumQ1 call promised recovery decision by Q2-end; Q2 deferred it to FY30 structural plan. Loses near-term credibility. If new products (Ashitaka, Takaib, Ghassanash) don't commercialize on schedule, Crop Care remains a drag through FY28.
Dairy margin lag: earnings headwind
Medium6% revenue growth insufficient vs milk procurement and feed cost inflation. Value-added products 49% of portfolio but margin still under pressure. If premiumization doesn't gain traction in H2, dairy profit remains a drag.
Astec enterprise demand weak: growth miss
MediumBrazil and US market toughness acknowledged. Prior 20%+ guidance absent from Q2 call. If R&D conversion pace and partnership commercialization don't accelerate in FY28, Astec remains a headwind to group earnings.
El Niño recovery timing uncertain: demand and commodity pressure
MediumOER at 18.9% vs 19.8% target suggests recovery slower than expected. If El Niño persists into H2, OER and Crop Care demand remain under pressure; margin recovery pushed to FY28.
How the street is positioned
The stock is trading at ₹586.2, down 33.14% from its all-time high and 15.83% above its 52-week low. More tellingly, it sits below its SMA20 (₹601.33), SMA50 (₹631.17), and SMA200 (₹591.53) — a weak technical setup despite double-digit fundamental revenue growth. The RSI at 44 (neutral) suggests no oversold bounce imminent; the drawdown is pricing in persistent near-term execution risk. Ownership is largely stable: FII at 6.48% (vs 6.32% prior Q, +16 bps), DII at 5.28% (down from 5.86%), promoters at 67.74% (unchanged). The FII uptick is marginal and contradicts the price weakness — institutions are watching, not adding aggressively. This suggests a 'wait and see' posture on whether Q3 margins recover and Crop Care new products gain traction. The valuation disconnect — a company delivering 16.7% revenue growth and 21.8% PAT growth YoY now trading 33% below ATH — is a warning flag rather than a bargain. It signals the market has priced in either (1) sustained near-term margin depression, (2) disappointment on Crop Care/Astec recovery timelines, or (3) macro weakness in agchem/dairy/oil palm. Until one of those resolves positively, the downward bias likely persists.
The debate
1 · Oil Palm capex second phase impact (Dec commissioning)
Verify whether phase two delivers incremental margin lift in Q3. If capex on time and EBIT margin expands back to 7.2–7.4%, the bull case gains credibility.
2 · Crop Care new product commercialization
Watch for revenue contribution from new launches (Ashitaka, Takaib, Ghassanash) and evidence of market traction. Q3 should show early-stage contribution; full impact FY28. Silence means recovery remains deferred.
3 · Dairy margin stabilization; input cost inflation trajectory
Q3 will reveal whether milk procurement, feed, packaging costs are stabilizing post-monsoon or remaining elevated. If stabilizing, premiumization gains will compound.
4 · El Niño recovery confirmation; OER trajectory to 19%+
Management said Oct OER was ahead of prior year; Q3 will confirm if recovery is sustained. If OER stabilizes at 19%+, Oil Palm profit recovery is on track and earnings confidence improves.
5 · FY27 full-year PAT guidance tone: maintained, raised, or quietly managed down
If management reaffirms double-digit PAT growth despite Q2 QoQ decline, the Street will ask for updated trajectory and Q3–Q4 guidance. If tone becomes cautious, expect 10–15% repricing down.
Q2 FY27 is steady execution on the revenue front — double-digit growth on track — but not a step-change for profit. The company is managing a transition: near-term headwinds (El Niño, agchem weakness, dairy cost inflation, Astec softness) are offsetting near-term margin recovery. The structural tailwinds (Oil Palm capex, Foods B2C, Animal Nutrition premiumization) are real and material, but H2 commissioning and commercialization timelines matter. Management is candid and positioned honestly; the stock's 33% drawdown from ATH is fair pricing of execution risk, not a clearance.
The number to track from here is operating margin trend. If Q3 OPM stabilizes and reverses toward 7.2%+, the bull case gains traction and the stock rerates. If it stays at 6.7% or dips further, the bear case (margin structure broken, recovery deferred to FY28) will dominate. That's the Q3 test.
Consolidated PAT +22% YoY to ₹103 Cr on lower tax; Crop Care swings to loss, H1 PBT down
PAT +21.83% YoY · revenue +16.65% · margins compressing
₹2,994.98 Cr
+16.65% YoY
₹102.75 Cr
+21.83% YoY
3.41%
+0.1pp YoY
₹5.99
Godrej Agrovet's primary consolidated numbers show revenue of ₹2,994.98 Cr, up 16.7% YoY and 4.9% QoQ, with PAT of ₹102.75 Cr, up 21.8% YoY but down 19.9% sequentially from Q1 FY27's ₹128.31 Cr. Standalone told a very different story — PAT fell 25% YoY to ₹132.59 Cr — but that gap is a basis artifact: standalone other income (largely dividends upstreamed from subsidiaries/JV) dropped to ₹20.31 Cr from ₹89.57 Cr a year ago, a timing effect that doesn't touch the Group's operating performance, which the consolidated line captures.
Q2 FY-2027 vs prior quarters
The YoY PAT growth is not operating-driven: total segment PBIT was actually down 3.2% YoY to ₹225.57 Cr, and the beat came from finance costs falling 30% (₹26.26 Cr vs ₹37.69 Cr) and tax falling 20% (₹40.49 Cr vs ₹50.72 Cr, effective rate 28.3% vs 37.6%). Within segments, Animal Nutrition — the largest business — grew PBIT 32% YoY to ₹92.79 Cr on 13.9% revenue growth, clear margin expansion. That was offset by Crop Care Business, which swung to a ₹5.55 Cr segment loss from a ₹16.33 Cr profit a year ago and from a strong ₹75.55 Cr in Q1 FY27 itself — the dominant reason for the QoQ PAT decline. Dairy's loss also widened to ₹3.87 Cr from ₹1.90 Cr.
The stock went into the print at ₹575.2, down 10.1% over the past month of trading.
For context: revenue is at a 6-quarter high.
FY27 consolidated revenue targeting double-digit growth (prior mid-teens PBT target now re-stated as double-digit); Oil Palm FFB volume high single-digit to early double-digit; Astec revenue growth at least 20%+; capex ₹300-350 Cr; Crop Care recovery decision by Q2-end.
— This quarter: missed
There is no consensus estimate on record for this specific quarter in our search, so vsStreet is unknown (Q1 FY27 had missed analyst EPS estimates by roughly 10%, per Simply Wall St, suggesting estimates have been running ahead of delivery lately). Against management's own guidance from the August 2026 concall — FY27 consolidated revenue targeted at double-digit growth, with the PBT target already walked back from mid-teens to double-digit — the revenue leg is broadly on track (H1 FY27 revenue ₹5,850.20 Cr, +12.9% YoY), but the profit leg is missing: H1 FY27 consolidated PBT is ₹324.37 Cr, down 3.3% YoY from ₹335.55 Cr, the opposite direction of a double-digit growth target. Management had also flagged a 'Crop Care recovery decision by Q2-end'; instead the quarter closed with the Crop Care CEO's resignation (Sep 21, 2026) and an interim appointment, alongside the segment's swing into loss — the decision point from the last call resolved into a leadership change rather than a stated recovery plan. No management press release or commentary accompanied this filing beyond the regulatory board-outcome letter.
W1
Crop Care turnaround under interim CEO — segment was +₹75.55 Cr in Q1 FY27 and -₹5.55 Cr in Q2; next print shows whether the 'recovery decision' management flagged materialises
W2
H1 FY27 consolidated PBT is down 3.3% YoY against a full-year double-digit growth target — H2 FY27 needs a sharp reversal to hit guidance
W3
Animal Nutrition segment margin — PBIT rose to 6.7% of segment revenue this quarter from prior levels; watch if input-cost tailwinds persist
No exceptional items this quarter (unlike FY26 annual labour-code/impairment items). Consolidated PAT includes NCI; owners' share was ₹115.21 Cr (+24.4% YoY) due to stake increases in Creamline Dairy (now 99.78%) and Astec LifeSciences (now 67.03%, post rights issue). Standalone PBT/PAT swing YoY is mainly a dividend-income timing effect (other income ₹20.31 Cr vs ₹89.57 Cr a year ago), not operating.